Expression of galectin-3 in nephrotic syndrome glomerulopaties in children

Folia Histochemica et Cytobiologica

Volumn 47, Issue 2, 2009, Pages 315-322

  Ostalska Nowicka, Danuta ^a   Nowicki, Michal ^a   Kondraciuk, Beata ^a   Partyka, Malgorzata ^a   Samulak, Dariusz ^a   Witt, Martin ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Children; Galectin 3; Glomerulopathy; Immunohistochemistry; Tubulopathy

Indexed keywords

GALECTIN 3; STEROID;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY COLLECTING TUBULE; KIDNEY CORTEX; KIDNEY DISTAL TUBULE; KIDNEY MEDULLA; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 73549093629     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0069-0     Document Type: Article

References (49)

1. Dumic J, Dabelic S, Floegel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616-635.
2. Liu FT. Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol. 2005;136:385-400.
3. Hsu DK, Zuberi RI, Liu FT. Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem. 1992;267:14167-14174.
4. Agrwal N, Sun Q, Wang SY and Wang JL. Carbohydrate-binding protein 35. I. Properties of the recombinant polypeptide and the individuality of the domains. J Biol Chem. 1993;268:14932-14939.
5. Mehul B, Bawumia S, Martin SR and Hughes RC. Structure of baby hamster kidney carbohydrate-binding protein CBP30, an S-type animal lectin. J Biol Chem. 1994;269:18250-18258.
6. van den Brule F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J. 2004;19:537-542.
7. Ho MK, Springer TA. Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol. 1982;128:1221-1228.
8. Joo HG , Goedegebuure PS, Sadanaga N et al. Expression and function of galectin-3, a beta-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol. 2001;69: 555-564.
9. Yu F, Finley RL Jr, Raz A and Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002;277:15819-15827.
10. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-3128.
11. Matarrese P, Fusco O, Tinari N et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties, Int J Cancer. 2000;85:545-554.
12. Ochieng J, Green B, Evans S et al. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta. 1998;1379:97-106.
13. Leffler H, Masiarz FR, Barondes SH. Soluble lactose-binding vertebrate lectins: a growing family. Biochemistry. 1989;28: 9222-9229.
14. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol. 1999;187:481-489.
15. Nishiyama J, Kobayashi S, Ishida A et al. Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol. 2000;157:815-823.
16. Pugliese G, Pricci F, Leto G et al. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes. 2000;49:1249-1257.
17. Sedivá A, Smetana K Jr, Stejskal J et al. Binding sites for carrierimmobilized carbohydrates in the kidney: implication for the pathogenesis of Henoch-Schoenlein purpura and/or IgA nephropathy. Nephrol Dial Transplant. 1999;14:2885-2891.
18. Kikuchi Y, Kobayashi S, Hemmi N et al. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19:602-607.
19. Saussez S, Nonclercq D, Laurent G et al. Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrolinduced kidney tumorigenesis in male Syrian hamster. Histochem Cell Biol. 2005;123:29-41.
20. Ostalska-Nowicka D, Zachwieja J, Nowicki M et al. Immunohistochemical detection of galectin-1 in renal biopsy specimens of children and its possible role in proteinuric glomerulopathies. Histopathology. 2007;51:468-476.
21. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol. 2002;13:3005-3015.
22. Kriz W, Lemley KV. The role of the podocyte in glomerulosclerosis. Curr. Opin. Nephrol Hypertens. 1999;8:489-497.
23. Barratt TM, Clark G. Minimal change nephritic syndrome and focal segmental glomerulosclerosis. In Holliday MA, Barratt TM, Ed A eds. Pediatric nephrology, 3rd edn. Baltimore, MD: Williams & Wilkins, 1994;767-787.
24. Bakker WW, van Luijk WH. Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome? Pediatr Nephrol. 1989;3:341-349.
25. Churg J, Habib R, White RH. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet. 1970;760:1299-1302.
26. Habib R, Girardin E, Gagnadoux MF et al. Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular "immune deposits". Pediatr Nephrol. 1988;2:402-408.
27. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
28. Armitage P, Gehan EA. Statistical methods for the identification and use of prognostic factors. Int. J Cancer 1974;13:16-36.
29. Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol. 1996;156:3939-3944.
30. Sato S, Ouellet N, Pelletier I et al. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol. 2002;168:1813-1822.
31. Sano H, Hsu DK, Yu L et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol. 2000;165:2156-2164.
32. Flotte TJ, Springer TA, Thorbecke GJ. Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. Am J Pathol. 1983;111:112-124.
33. Liu FT, Albrandt K, Mendel E et al. Identification of an IgE-binding protein by molecular cloning. Proc Natl Acad Sci USA. 1985;82:4100-4104.
34. Schroder HC, Ushijima H, Theis C et al. Expression of nuclear lectin carbohydrate-binding protein 35 in human immunodeficiency virus type 1-infected Molt-3 cells. J. Acquir Immune Defic Syndr Human Retrovirol. 1995;9:340-348.
35. Liu FT, Hsu DK, Zuberi RI et al. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol. 1995;147:1016-1028.
36. Frigeri LG, Zuberi RI, Liu FT. Epsilon BP, a beta-galactosidebinding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells. Biochemistry. 1993;32: 7644-7649.
37. Truong MJ, Gruart V, Kusnierz JP et al. Human neutrophils express immunoglobulin E (IgE)-binding proteins (Mac-2/epsilon BP) of the S-type lectin family: role in IgE dependent activation. J Exp Med. 1993;177:243-248.
38. Truong MJ, Gruart V, Liu FT et al. IgE binding molecules (Mac-2/epsilon BP) expressed by human eosinophils. Implication in IgE-dependent eosinophil cytotoxicity. Eur J Immunol. 1993;23:3230-3235.
39. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA. 1996;93:6737-6742.
40. Yoshii T, Fukumori T, Honjo Y et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2002;277:6852-6857.
41. Akahani S, Nangia-Makker P, Inohara H et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272-5276.
42. Fukumori T, Takenaka Y, Oka N et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res. 2004;64:3376-3379.
43. Hotta O, Yusa N, Ooyama M and Taguma Y. Urinary macrophage counts and ratio to T lymphocytes: possible use in differential diagnosis and management of glomerular disease. J Clin Lab Anal. 1996;10:205-208.
44. Oda T, Hotta O, Taguma Y et al. Clinicopathological significance of intratubular giant macrophages in progressive glomerulonephritis. Kidney Int. 1998;53:1190-1200.
45. Bullock SL, Johnson TM, Bao Q et al. Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol. 2001;12:515-523.
46. Hughes RC. Galectins in kidney development. Glycoconj J. 2004;19:621-629.
47. Chiu MG, Johnson TM, Woolf AS et al. Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease. Am J Pathol. 2006;169:1925-1938.
48. Nio J, Takahashi-Iwanaga H, Morimatsu M et al. Immunohistochemical and in situ hybridization analysis of galectin-3, a b-galactoside binding lectin, in the urinary system of adult mice. Histochem Cell Biol. 2006;126:45-56.
49. Winyard PJ, Bao Q, Hughes RC and Woolf AS. Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol. 1997;8:1647-1657.